62482-32-0

Usage

Uses

Used in Pharmaceutical Industry:
5-chloroquinoline-4-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for its reactivity and structural properties, contributing to the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
As a derivative of quinoline, 5-chloroquinoline-4-carboxylic acid is used as a building block in the synthesis of complex organic molecules, particularly in the creation of novel chemical entities with specific functionalities and properties.
Used in Material Science:
5-chloroquinoline-4-carboxylic acid's chemical reactivity and structural features make it a candidate for use in the development of new materials with tailored properties, such as in polymers, coatings, or other advanced materials for various industrial applications.
Used in Research and Development:
5-chloroquinoline-4-carboxylic acid serves as a valuable research tool in academic and industrial laboratories, where it is utilized to explore new chemical reactions, mechanisms, and the synthesis of innovative compounds for diverse applications.

InChI:InChI=1/C10H6ClNO2/c11-7-2-1-3-8-9(7)6(10(13)14)4-5-12-8/h1-5H,(H,13,14)

Upstream product

• 62482-33-1 5-chloroquinoline-2,4-dicarboxylic acid 
• 6344-05-4 4-chloroisatin 

Downstream Products

• 116557-07-4 5-chloro-quinoline-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold

Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold. We have explored the effects of substituting the quinoline ring and varying the position of its sp2 hybridized nitrogen atom. The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indices (>10 3) with respect to both the DPPs and PREP. Preliminary experiments on a representative inhibitor demonstrate that plasma stability, kinetic solubility, and log D of this class of compounds can be expected to be satisfactory.